Our Research Model
Paradigm
By working together, we reduce redundant efforts, identify the most promising biological targets, and prioritize the best compounds for optimization.
![](https://www.tbdrugaccelerator.org/wp-content/uploads/2021/11/image-9-697x135.png)
The standard non-collaborative discovery model has not been particularly fruitful. Relatively few new drugs have been launched over the last 50+ years and there are no new first-line regimens.
We employ the following discovery paradigms:
- Phenotypic screening followed by target ID
- Target based screening
- Virtual Screening
- Information based
- Known antibacterial drugs
- Natural products with antibiotic activity
- Compounds with activity against orthologs
Collaboration and Teamwork
![](https://www.tbdrugaccelerator.org/wp-content/uploads/2021/11/image-10-697x368.png)
The TBDA is a new paradigm for drug discovery and offers an approach that addresses many of the bottlenecks in the way TB drugs are currently discovered.
How We Work
![](https://www.tbdrugaccelerator.org/wp-content/uploads/2021/11/image-6-697x156.png)
Focus Areas
We are currently focusing on nine areas which we believe will contribute to improved therapies and regimens, they are:
- Chemical diversity
- Phenotypic screening
- Target essentiality and vulnerability
- Genetically modified whole-cell activity (hypomorphs)
- Metabolic impact
- Diverse animal models
- Mimicking different compartment with multiple conditions (e.g. pulmonary lesions)
- Lesion and Mtb PK/PD
- Combination prioritization (in vitro and in vivo)
Member Organizations
Member organizations are a mix of academic institutions, pharma and biotech companies, research institutes and product development partners.